Clinical and demographic characteristics of the patients enrolled in the study
| Case | Age, years | Sex | Duration, months | SLEDAI | Proteinuria, mg | WBC, 109 cells/litre | Hb, g/litre | PLT, 109 cells/litre | Cr, mg/dl | ALB, g/litre | GFR, ml/min | Anti-dsDNA, titre | ANA, titre | Treatment at the time of MSCT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 23 | F | 12 | 12 | 2325 | 6.9 | 134 | 332 | 0.68 | 21.1 | L: 33.28, R: 32.50 | 1:2000 | 1:1000 | P 20 mg/day+CTX 0.4/2 weeks×6 months |
| 2 | 20 | F | 29 | 20 | 3690 | 3.2 | 98 | 125 | 1.73 | 36.7 | L: 23.12, R: 22.14 | 1:500 | 1:2000 | P 25 mg/day+CTX 0.4/2 weeks×18 months |
| 3 | 17 | M | 24 | 14 | 2725 | 6.2 | 101 | 228 | 0.57 | 16.9 | L: 42.24, R: 46.21 | 1:2000 | 1:1000 | P 30 mg/day+CTX 0.4/2 weeks×24 months |
| 4 | 16 | F | 51 | 12 | 1318 | 3.9 | 132 | 132 | 0.64 | 39.8 | L: 55.28, R: 54.20 | 1:2000 | 1:2500 | P 30 mg/day+CTX 0.4/2 weeks×24 months |
| 5 | 41 | F | 180 | 9 | 2078 | 3.4 | 94 | 109 | 0.76 | 35.7 | L: 41.20, R: 45.06 | 1:500 | 1:500 | P 20 mg/day+CTX 0.4/2 weeks×24 months |
| HCQ 0.2 twice daily×3 months | ||||||||||||||
| 6 | 21 | F | 72 | 10 | 1957 | 8.7 | 89 | 313 | 0.81 | 28.7 | L: 45.13, R: 45.45 | 1:100 | 1:500 | P 20 mg/day+CTX 0.4/2 weeks×18 months |
| MMF 0.75 twice daily×3 months | ||||||||||||||
| 7 | 31 | F | 60 | 14 | 1508 | 6.2 | 114 | 201 | 0.55 | 34.2 | L: 35.27, R: 40.83 | 1:2000 | 1:500 | P 20 mg/day+MMF 0.75 twice daily×6 months |
| 8 | 29 | F | 120 | 8 | 2028 | 5.6 | 93 | 114 | 0.48 | 30.1 | L: 40.51, R: 51.68 | 1:1000 | 1:500 | P 20 mg/day+CTX 0.4/2 weeks×36 months |
| 9 | 21 | F | 120 | 20 | 1496 | 4.4 | 60 | 172 | 5.36 | 30.7 | L: 12.06, R: 16.84 | 1:1000 | 1:500 | P 20 mg/day+CTX 0.4/2 weeks×15 months MMF 1.0 twice daily×2 months |
| 10 | 37 | F | 192 | 15 | 922 | 1.3 | 58 | 24 | 4.4 | 23.0 | L: 27.12, R: 21.85 | 1:500 | 1:1600 | P 25 mg/day+CTX 0.4/2 weeks×13 months. MMF 0.5 twice daily×3 months |
| 11 | 42 | F | 120 | 12 | 3992 | 4.1 | 112 | 175 | 0.93 | 18.6 | NA | 1:2000 | 1:1000 | P 20 mg/day+CTX 0.4/4 weeks×25 months. |
| MMF 0.5 twice daily×3 months | ||||||||||||||
| 12 | 12 | F | 24 | 10 | 2257 | 5.1 | 128 | 221 | 0.96 | 31.8 | L: 62.28, R: 82.69 | 1:1000 | 1:100 | P 20 mg/day+CTX 0.4/2 weeks×10 months |
| 13 | 41 | F | 132 | 10 | 2329 | 6.5 | 105 | 178 | 1.52 | 28.4 | NA | 1:2000 | 1:500 | P 20 mg/day+CTX 0.4/4 weeks×21 months |
| 14 | 30 | F | 84 | 12 | 2000 | 4.2 | 137 | 168 | 2.55 | 30.5 | L: 11.85, R: 9.87 | 1:2000 | 1:1000 | P 35 mg/day+CTX 0.2/1 weeks×19 months |
| HCQ 0.1 twice daily×4 months | ||||||||||||||
| 15 | 44 | F | 132 | 14 | 5655 | 5.9 | 72 | 247 | 1.08 | 24.6 | L: 35.29, R: 32.73 | 1:500 | 1:500 | P 20 mg/day+CTX 0.4/2 weeks×16 months |
| HCQ 0.1 four times a day×3 months |
All laboratory results were taken at the time of MSCT. Duration: from the first symptom of lupus to the time receiving MSCT.
ALB, albumin; ANA, anti-nuclear antibodies; Cr, creatinine; CTC, cyclophosphamide; CTX, collagen; dsDNA, double-stranded DNA; GFR, glomerular filtration rate; Hb, haemoglobin; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MSCT, mesenchymal stem cell transplantation; NA, not applicable; P, predonisolone; PLT, platelet; SLEDAI, systemic lupus erythematosus disease activity index.